Venus receives GLP accreditation for its R&D centre

Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies Limited, has been accredited for Good Laboratory Practices (GLP) and norms on Organisation for Economic Cooperation and Development (OECD) Principles by the National GLP and Compliance Monitoring Authority (NGCMA).

With this, VMRC, a leading research-based global pharma company, has joined the list of top 25 testing laboratories in India and eight Indian pharmaceutical companies who have received GLP approval.

Manu Chaudhary, Joint Managing Director, Venus Remedies Limited, and Director, Research, VMRC, termed it as a landmark achievement.

In a statement, he said: "This GLP accreditation, one of the most coveted certifications for R&D capabilities, is yet another significant milestone in our efforts to ensure product quality, safety, reliability and excellence while preserving and improving human life through innovation. It gives our research an international credibility."

The certification is an attestation of the consistent reliability of the company's R&D tests and calibration as well as its documented quality management system, the statement said.

It further said that besides this, the GLP certification meets the company's strategic vision to bring to the world novel breakthroughs that cater to critical care and super- speciality segments, including anti-infective (anti-microbial resistance), anti-cancer, neurology, pain management and wound care.

Led by a team of 75 highly professional, trained scientists, VMRC is dedicated to developing novel and innovative research products on a par with global quality standards, it added.

The VMRC team has secured over 90 patents for its research products from across the world, including countries like USA, Australia, Japan, European Union constituents and others.

"It is a matter of great pride for us to have received GLP certification for our Venus Medicine Research Centre. We are now the eighth pharmaceutical company in India with GLP accreditation.

"Any R&D-related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as USA, Japan and various European countries," said Dheeraj Aggarwal, Chief Financial Officer (CFO), Venus Remedies Limited.